nal series of 20 patients, approximately 55% achieved response, defined by a 50% reduction in HRSD-17 scores after 12 months of continuous DBS stimulation. 17 These patients were treated at a single center and with stimulation applied using a pulse generator that delivered constant-voltage stimulation.
The purpose of the present study was to replicate these findings across several centers using the Libra DBS system.
Methods

Patients and HRSD Testing
We conducted a 3-center prospective open-label trial of SCG DBS for 12 months in patients with TRD. The inclusion and exclusion criteria for study entry are shown in Table 1 . The study was approved by the institutional review boards of the 3 institutions (University of British Columbia, McGill University, and University Health Network), and written informed consent was obtained from each participant. Each patient underwent 2 baseline psychiatric evaluations 1 month apart, and the depression scores were averaged for the purposes of determining the baseline at study entry. If the second HRSD-17 score was less than 18, a third evaluation was required. If at the third the HRSD score was again less than 18, the case was deemed a "screen failure" and excluded from the study. The demographic information of the patients is shown in Tables 2-4 .
Surgery
Surgery was performed as previously described. 17, 21 Briefly, a local anesthetic was used and a Leksell stereotactic frame was applied. Patients then underwent brain imaging in which a 3D MR imaging acquisition was used. The reformatted brain images were processed on a workstation, and bilateral targets were chosen within the SCG extending from the lower gray matter bank to the central white matter and to the upper gray matter bank of the gyrus. The surgical procedure was also performed after application of a local anesthetic. Bilateral bur holes were made at the level of the coronal suture, 2 cm from the midline. Libra electrodes (St. Jude Medical) were inserted at the target sites and fixed to the skull. When the frame was removed, general anesthesia was induced and the Libra DBS electrodes were tunneled, using a connector, toward the infraclavicular area where they were connected to a Libra constant-current internal pulse generator (St. Jude Medical). The technical aspects of implanting Libra DBS and Medtronic systems (as used in our previous reports 17, 21 ) were similar.
Electrode Location
Postoperative T1-and T2-weighted MR images were merged and reformatted along the anterior-posterior commissure line. Deep brain stimulation electrodes were visualized in 3 planes and the sphere-shaped artifacts corresponding to each electrode contact were targeted. We defined as active contacts those being used as the cathodes at 6 months. Because of the variability in the anatomy of the prefrontal cortex and SCG across individuals, coordinates relative to the midcommissural point are less useful. To overcome this, we assessed the location of the active contacts relative to the grid system we have previously published. 10 This system consists of 2 lines, 1 in the anteroposterior and the other in the dorsoventral axis. The anteroposterior line extends from the anterior commissure to the projection of the anterior aspect of the corpus callosum. The dorsoventral line extends from the inferior edge of the corpus callosum to the most ventral aspect of the frontal lobe. Each line was normalized into 100 equal units, and data were converted into percentages, as previously described. 10 In the mediolateral plane we calculated the distance between the center of the active contacts and the edge of the cortical surface. Data from the right and left electrodes were combined for statistical purposes. Statistical analyses were conducted using the ANOVA with significance set at p ≤ 0.05.
Stimulation Programming Visits
The stimulation parameters were chosen based on our previous experience and on the patients' responses to stimulation over a period of 1-2 weeks. Average stimulation settings on the first visit, at 6 months, and at 12 months are shown in Table 5 .
Outcome Measures
The HRSD-17 was the primary outcome measure, and response was defined as a minimum 50% reduction in the HRSD-17 score from baseline (that is, RESP50). The HRSD-17 was administered by the treating psychiatrist at all study visits, including at baseline and at 3, 6, and 12 months after DBS. The CGI-S Scale was a secondary measure.
Results
Twenty-two patients were enrolled in the study, although 1 patient was excluded because of a medical comorbidity, leaving 21 patients who underwent lead implantation. The proportion of patients in the RESP50 group was 57% at 1 month, 48% at 6 months, and 29% at 12 months. The mean decline in HRSD-17 scores in the 21 patients is shown in Fig. 1 . At 2 months, there was a decline of 40.3% ± 29.8%. At 6 months the decline was 43.3% ± 31.3%, and at 12 months it was 41.4% ± 23.0%.
The reductions in depressive symptomatology were associated with improvements in disease severity and global improvements in the patients. As shown in Fig. 2 , patients shifted from being severely ill to being less ill after surgery, and the majority of the patients improved with surgery. At 12 months none of the 20 patients who remained in treatment were worse than at baseline (Fig. 2) .
Position of Active Electrode Contacts
The positions of the DBS contacts used for stimulation are projected onto a brain atlas as shown in Fig. 3 . We compared the position of the active electrodes at the 3 study sites. There were no differences in the location of contacts used for stimulation at 6 months across sites when internal landmarks of the medial frontal lobe were illness w/ at least a total of 4 lifetime episodes (including current episode ≥12 mos) (a new episode starts after a remission of a minimum of 2 mos) documented resistance to at least 4 depression treatments in a lifetime; cognitive behavioral therapy considered an effective form of treatment in current episode: documented resistance (i.e., persistence of the major depressive episode) to a minimum of 3 adequate depression treatments from at least 3 different treatment categories (SSRIs, TCAs, other antidepressants, lithium addition, irreversible MAO inhibitor); adequacy of treatments defined by a score of at least 4 (or 3, plus clear evidence that the dose at 4 could not be tolerated) according to the ATHF criteria in the current episode: documented resistance to ECT (at least 6 sessions [i.e., a minimum score of 3 according to ATHF criteria]) or <6 treatments if there is clear evidence of inability to tolerate more, or refused, or withdrew consent after ECT was recommended premenopausal women must agree to use acceptable methods of birth control HRSD-17 score ≥20 Global Assessment of Function Score <50 Modified Mini-Mental State Examination Score ≥27 stable on current antidepressant medication regimen or medication free ≥4 wks able to give informed consent in accordance w/ institutional policies able to comply w/ all testing & follow-up requirements defined by the study protocol other medical conditions must be stable for at least 1 yr (conditions that require intermittent use of steroids or chemotherapy excluded) confirmed disease state & surgical suitability by independent psychiatric examination exclusion criteria diagnosed w/ a bipolar I or bipolar II disorder by DSM-IV-TR criteria derived from the MINI currently meets the DSM-IV-TR criteria for a major depressive episode w/ atypical symptoms has alcohol or substance dependence within 12 mos, excluding nicotine; alcohol or substance abuse w/in 6 mos, excluding nicotine current substantial suicidal risk as defined by a plan or clear immediate intent for self-harm, or made a serious suicide attempt w/in the last year that has required an emergency department visit or hospitalization has a neurological disease that impairs motor, sensory, or cognitive function or that requires intermittent or chronic medication (e.g., Parkinson disease, migraine, stroke, Huntington disease, head trauma) clinically relevant abnormality on MRI has primary or serious (requiring additional treatment) comorbid obsessive compulsive disorder, posttraumatic stress disorder, panic disorder, bulimia, or anorexia in the last year by DSM-IV-TR criteria derived from the MINI meets criteria for a severe cluster B personality disorder (i.e., borderline, narcissistic, or antisocial) in the last 12 mos by DSM-IV-TR criteria derived from the Structured Clinical Interview for DSM-IV (or the SCID II) borderline personality section established cardiovascular disease as evidenced by a history of angina, myocardial infarction, or the need for cardiac drugs (w/ the exception of cholesterol-lowering agents) has cardiac pacemaker/defibrillator or other implanted stimulator likely to relocate or move to a location distant from study site w/in 1 yr of enrollment past intracranial neurosurgery pregnant or has plans to become pregnant in the next 12 mos has current or lifetime psychosis by DSM-IV criteria * ATHF = Antidepressant Treatment History Form; ECT = electroconvulsive therapy; MAO = monoamine oxidase; MINI = MiniInternational Neuropsychiatric Interview; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant. considered (Fig. 3) . In the mediolateral plane, contacts at the 3 study institutions were on average between 5-7 mm from the medial cortical surface.
Deep Brain Stimulation Parameters Over Time
The stimulation parameters used in the patients over 12 months are shown in Table 5 . In some cases these parameters required adjustments over time. So as not to confound the study, the patients' medications were maintained unchanged from baseline through 6 months.
Adverse Effects
Suicide was the most serious adverse effect in this study. One patient committed suicide, and another patient attempted suicide. The patient who committed suicide did so at an early stage of the follow-up (after the 8th week). The death was due to an overdose of medications. The patient who attempted suicide was at a different institution. The patient was between the Week 4 and Week 5 follow-up visits. The underlying trigger was thought to be a family matter.
In the current study, nausea and vomiting were recorded in 7 patients. At present, it is unclear whether this represents a side effect of stimulating this region, was a consequence of the interaction between stimulation and medications, or was due to completely unrelated causes.
In another patient, there was a lead extension malfunction immediately after surgery requiring extension replacement. The stimulation was reactivated immediate- ly after the revision surgery. One patient had superficial skin erosion at the bur hole site. This appeared 7 weeks after device activation, and the skin incision was revised. The serious and not serious adverse effects are summarized in Table 6 .
Discussion
Our results show that using a reduction of 50% in the HRSD-17 score as a criterion, 48% and 29% of TRD patients responded to SCG DBS at 6 and 12 months, respectively. Responses seen at 3 months tend to be maintained at 1 year. The reduction in depression scores is associated with significant clinical global improvements and amelioration of depression severity. The results of this multicenter study suggest that the SCG can be reliably targeted for DBS electrode implantation and that the clinical effects of SCG DBS for TRD are robust and reproducible across centers.
The apparent drop in efficacy from a response rate of 48% at 6 months to 29% at 12 months is potentially worrisome but may be somewhat of an artifact of the data analysis. A proportionately large number of patients are hovering in the range of a 40%-50% reduction in depression scores in the 6-12-month period. While depression scores in 29% of the patients improved by 50% or more at 12 months, in 62% of the patients the scores improved by 40% or more at the same time point. This occurred because 4 of 10 patients dropped from the 50% to the 40% range at 12 months, a small change that is likely noise but which has a large impact when using the 50% cutoff for response in a series with a relatively small number of participants. Our recently reported long-term follow-up in the original 20 patients at 3-6 years after surgery suggests that the benefits of DBS for depression are maintained over time. 12 Our results raise several questions. A major limitation of this open-label study is that a placebo effect cannot be ruled out. It is not entirely clear why some patients respond and others do not. Several possibilities include disease heterogeneity, individual anatomical variability, differences in stimulation requirements, variable time courses of the effects of stimulation including delay, and carryover effects of stimulation.
Similarly, the choice of target remains an issue. Other than the SCG, it is clear that other brain targets may also be useful for treating TRD, including the nucleus accumbens and the anterior limb of the internal capsule. 1, 18 The specific attributes and potential uses of each of these possible therapeutic targets will require much more investigation.
It is not clear whether the constant-current mode of delivery we used offers a significant difference from the previously used clinical DBS systems that have voltagecontrolled pulse generators. The use of voltage-controlled stimulation results in voltage distributions in the target neural tissues that depend on the impedance of the electrode-tissue interface. 2, 23 The impedance of the DBS electrode-tissue interface has been shown to fluctuate both after implantation and during stimulation. 15 These varying impedance conditions are suspected to produce instability in the voltages produced in the target neural tissues during voltage-controlled DBS, and they may be at least partially responsible for the need to adjust stimulation parameters during the system's initial programming process. Unlike voltage-controlled DBS, current-controlled DBS regulates the current through the electrode-tissue interface. In theory, the voltages generated in the target brain tissues by current-controlled DBS should be fairly independent of the electrode impedance.
14 This increased stability in the extracellular voltages produced from stimulation could, at least in theory, help stabilize the therapeutic efficacy of the stimulation parameters selected. That being said, once scar formation is complete around the electrode, the brain-electrode interface becomes relatively stable. This can be appreciated in other applications of DBS in which changes in stimulation parameters are not often required after the first weeks or months of treatment. At present, it is unclear whether constant-current systems will have a practical advantage over constantvoltage systems for this indication.
In general the surgical procedure was well tolerated. There were a large number of adverse effects (Table 6 ).
None of the adverse effects was thought to be the result of the stimulation per se. They were likely related to the patient population. No unexpected adverse events were noticed during this trial. One of 21 patients committed suicide 8 weeks into the trial. Treatment resistance is a feature commonly associated with suicidality in individu- The vertical axis is the number of patients at each time point. At baseline, the majority of patients were extremely ill and among the most ill patients (Categories 6 and 7). With time, patients improved, shifting to markedly ill (Categories 4 and 5), mildly ill (Categories 2 and 3), and in some cases normal (Category 1). The CGI-S scores at baseline were available for less than the entire sample of 21 patients. Lower: Number of patients who improved (a, Categories 1-3), showed no change (b, Category 4), or worsened (c, Categories 5-7) after SCG DBS, as assessed using the CGI-S improvement scores at 3, 6, 9, or 12 months. With time after DBS, most patients improved. Data were not available for the entire sample of 21 patients. (CGI scale: Considering your total clinical experience with this particular population, how mentally ill is the patient at this time? 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill patients.) als with depression. 26 In fact, patients with TRD commit twice as many suicides as patients who respond to therapy. 16 Suicides have been reported in other studies of DBS for TRD, 1 highlighting the need for active psychiatric follow-up of this population in the postoperative period.
As a consequence of this work, together with previous experience with DBS at this target in other patients, it is possible to conclude that SCG appears reasonably safe and shows considerable promise in helping patients with TRD. What is now required is a controlled study in a larger number of patients to determine the safety and effectiveness of this approach.
Conclusions
The effects of SCG DBS in patients with TRD were investigated in a 3-center prospective open-label trial. Overall, patients had an RESP50 of 57% at 1 month, 48% at 6 months, and 29% at 12 months. Reductions in depressive symptomatology were associated with amelioration in disease severity in patients who responded to stimulation. Findings from this study corroborate the results of previous reports showing that outcome of SCG DBS may be replicated across centers.
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